news
Insilico and Qilu partner to create generative AI cardiometabolic drugs
Insilico Medicine and Qilu Pharmaceutical Group are expanding their existing R&D collaboration to apply generative AI to cardiometabolic drug discovery.
List view / Grid view
Artificial Intelligence
news
New generative AI method could make drug discovery faster
A newly developed AI-driven technique could dramatically speed up the discovery of drugs and advanced materials, enabling scientists to design chemically valid, property-targeted molecules in minutes rather than years.
news
How ageing cells affect brain development and neurodegeneration
New research has revealed how cellular senescence – the process in which ageing cells change function – shapes human brain structure from development to old age, improving our understanding of brain ageing and neurodegenerative diseases.
article
Rethinking drug discovery through transcription factor biology
Complex diseases rarely have single targets. By focusing on transcription factor activity and disease signatures, Scripta Therapeutics is taking a different approach to identifying the drivers of pathology.
article
2026: the year AI stops being optional in drug discovery
AI is moving from a supporting role into the core of drug discovery. By 2026, it is expected to shape how targets are chosen, how biology is analysed and how development decisions are made.
news
insitro expands AI drug discovery with CombinAbleAI acquisition
insitro has acquired Israeli AI therapeutics company CombinAbleAI and launched its TherML platform, creating an end-to-end, modality-agnostic system for designing small molecules, antibodies, oligonucleotides and other complex biologics.
article
AI steps into drug safety: predicting liver injury earlier than ever before
Drug-induced liver injury remains one of drug development’s most costly pitfalls. Now, AI and transcriptomics may offer a way to spot risks long before they reach patients.
news
Schrödinger partners with Lilly TuneLab on AI drug discovery
Schrödinger has announced a collaboration with Eli Lilly’s TuneLab platform, integrating advanced AI-driven drug discovery workflows into its LiveDesign enterprise informatics system.
article
Quality over quantity: drug discovery automation in 2026
Automation in 2026 is no longer judged by the volume of experiments, but by the reliability of the evidence they produce. As complex biology and tighter budgets collide, industry leaders are pivoting toward automated workflows to secure the data integrity required for confident, early-stage decision-making.
news
New AI genomics platform targets kidney and cardiorenal disease
Seattle-based biotech company, Variant Bio, have launched Inference, an AI-powered genomics platform designed to accelerate drug discovery and identify genetically supported targets.
news
New Lumos AI platform targets precision in mental health drugs
Headlamp Health has launched Lumos AI®, a new decision-support platform designed to bring greater precision to neuroscience drug development.
article
Agentic AI: teaching machines to think like scientists
What happens when AI stops guessing and starts reasoning? Agentic AI is bringing scientific logic into the heart of drug discovery.
news
Insilico secures $888million Servier partnership for AI oncology
Insilico Medicine and Servier have announced a multi-year collaboration to accelerate the discovery of new cancer therapies, using artificial intelligence to tackle challenging oncology targets and shorten early-stage drug development timelines.
article
The data fragmentation problem holding drug discovery back
The DMTA cycle depends on clear data flow, yet most labs still work across disconnected systems. Sean McGee, Director of Product at Certara, explains how better infrastructure and AI can help teams work faster and make decisions with more confidence.
news
New AI model links genetic mutations to specific diseases
Scientists have developed a new artificial intelligence tool that can identify harmful genetic mutations and predict the types of diseases they are likely to cause, offering faster diagnosis and new opportunities for drug discovery.
